RA0388

antibody from Oursmab

Targeting: IL3RA CD123

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0388

Provider

Oursmab

Product name

Pivekimab (Biosimilar Reference Antibody) (IL3RA)

Antibody type

Monoclonal

Description

Pivekimab is a novel human IgG1 monoclonal antibody designed for targeted immunotherapy, which uniquely and simultaneously binds to both interleukin-3 (IL-3) and its receptor subunit CD123. This dual-targeting mechanism is intended to disrupt the IL-3 signaling pathway by sequestering the cytokine and blocking its interaction with the receptor on the cell surface. Developed primarily for the treatment of certain hematologic malignancies, pivekimab aims to inhibit the survival and proliferation of cancerous cells, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML) cells, that often overexpress CD123 and depend on IL-3 for growth and survival.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.